In vivo tumor efficacy studies
In vivo tumor efficacy studies were performed to evaluate the anti-tumor effects of antibody drug conjugates (ADCs) derived from Tcho and Tcmax conjugated to maytansanoids and auristatins. The ADCs were tested in an NCI-N87 stomach cancer xenograft model. This cell line has an overexpressed HER-2 oncogene, and has been described as insensitive to HER-2-inhibiting drugs. 
NCI-N87 implantation
On the day of implantation, NCI-N87 cells were trypsinized and allowed to detach from flasks. Trypsin was then neutralized with complete media and cells were spun at 400 x g.
Media was aspirated and cells were resuspended in 50:50 *Cultrex:RPMI (no supplementation) at a concentration of 5 x 10 7 cells / mL. A volume of 100 µL was injected S-5 into the right hind flank of each animal (a total of 5 x 10 6 cells).
[Cultrex: BME, Type 3, Trevigen Cat. # 3632-005-02, Lot # 40498J17]
Study Arms and Treatments
Tumor volumes were monitored, and when tumor volume reached ~120 mm 3 , mice were stratified and placed into (12) treatment groups of (10) mice as outlined in Table S1 . 
